



## **GENOMICA (PharmaMar Group) & Huasin Science completes the first CLART<sup>®</sup> diagnostic equipment for the China market**

- **In February, GENOMICA signed a contract with the Chinese company for the production and marketing of a Human Papilloma Virus (HPV) diagnostic kit in the Asian country.**
- **The Chinese delegation traveled to Spain where they have received the necessary training to learn how to use the equipment, designed with a specific software for them.**
- **The new equipment is capable of simultaneously analyzing 96 patient samples in less than 5 hours.**

**Madrid, November 27<sup>th</sup>, 2019.-** GENOMICA, the molecular diagnostics company belonging to the PharmaMar Group (MSE:PHM), begins to materialize its first contract in China with the medical equipment company, HuaSin Science, to lead the global challenge of the early diagnosis of cervical cancer in China. Following the signing of the contract at the beginning of 2019 and after 8 months work, production of the first 6 automatic units, fully adapted to the Asian brand has been completed, including a specific corporate image design, as well as user software in Chinese. The molecular diagnostic kits based on GENOMICA's CLART<sup>®</sup> technology, will be produced by HuaSin Science, will allow the analysis of the HPV.

During their visit to Genomica in Spain, the Chinese delegation has received the necessary training to process the samples, use and maintain equipment and understand the functional characteristics and technical specifications of the diagnostic kit, which will be used to detect HPV in millions of women in China.

With the training of personnel and the delivery of this equipment, the first milestone of this agreement has been completed, the next step consisting in the beginning of the registration process by the company HuaSin Science of the HPV diagnostic kits and automation equipment.



HPV is the most common sexually transmitted infection in the world that can cause cancer. According to statistics, between 75-80% of sexually active men and women may contract this virus at some point in their lives, accounting for 10% of cervical cancer cases in women.

China accounts for 25% of the half a million cases of cervical cancer diagnosed each year in the world. Early diagnosis of HPV could greatly prevent the further development of cervical cancer in more than 125,000 women from the Asian giant, a cancer that causes about 50,000 deaths a year.

The new diagnostic kit, designed with specific software for the Chinese company, allows for the analysis of 96 simultaneous samples from patients in approximately 5 hours. This tool will allow the analysis and identification of all HPV genotypes, of which 14 have the capacity to produce cancer.

The molecular diagnosis kit, which will be marketed in China under the name "Di Bao", provides the medical professional with the necessary information to make clinical decisions regarding the treatment and monitoring of the patient. This kit complements, and in some cases replaces, the traditional cytology because it shows whether the HPV virus has produced any cellular alteration, while the molecular diagnostic kit indicates whether the virus is present and what type of genotype it is. An early diagnosis of the virus increases the chances of cure and survival.

GENOMICA thus becomes the first Spanish Company to start penetrating the HPV molecular diagnosis market in China.

GENOMICA opened its subsidiary in Wuhan, China, in January 2018, becoming the first Spanish molecular in vitro diagnostic manufacturer with a subsidiary in China. With the delivery of this equipment, the milestones and deadlines foreseen in the agreement signed by both companies at the beginning of 2019 continue to be met. HuaSin Science obtains with this contract the exclusive rights to produce and distribute the kit under its own brand, "Di Bao", a fully automated HPV genotyping analysis platform, based on CLART<sup>®</sup> technology designed by GENOMICA.



## About Cervical Cancer

Cervical cancer is the fourth most common cancer in women with 570,000 new cases in 2018, accounting for nearly 7% of all female cancers.

The main causes of cervical cancer are human papillomavirus (HPV), of which an increasing number of subtypes have been shown to be high-risk types for cancer. Such a death rate from cervical cancer could be reduced through prevention, early diagnosis, effective detection, and treatment programs.

## Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

## About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

## About GENOMICA

GENOMICA is highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability and automation.

Our main objective is to maintain leadership in genomics applications within the Spanish market, and to internationally extend our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART®.

## About HuaSin Science

Established in October 1989 and headquartered in Guangzhou, China, is a professional enterprise who distributes clinical laboratory instruments, medical devices and reagents, manufactures in vitro diagnostics products and provides third-party clinical laboratory services. HuaSin Science has set up branches and offices in 28 cities nationwide and its sales network covers every part of China. HuaSin Science is dedicated to bring state-of-the-art medical devices and reagents to China. HuaSin Science also manufactures high quality and affordable reagents for clinical diagnosis under "DiBao" brand which are well-accepted by clinical laboratories in China. HuaSin's third-party clinical laboratory, Guangzhou KangDu Clinical Laboratory was established in 2003 and has been providing premier services for hospitals in Guangdong. Upholding the motto "professional product, professional service" and integrating research, distribution, production and service, HuaSin Science is striding on the right track to prosperity and to meet the need of Chinese people for better health.

## Media Contact:

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127



Miguel Martínez-Cava – Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464  
Phone: +34 918466000



**Investor Relations:**

Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)